Health Canada Approves Phase 1 Study of Vaporized Cannabinoid-derived Treatment PPP001 for Chronic Pain: Fibromyalgia News Today
Tetra BioPharma has announced that the Therapeutic Drug Directorate at Health Canada has issued a “No objection letter” in approving a Phase 1 study to test a vaporized version of PPP001 for the treatment of #chronic-pain, the main feature of #fibromyalgia.
The study will investigate the pharmacokinetics — the time the body takes to absorb, distribute, and excrete the substance — and the safety of the vaporized medicine.
PPP001 is a #cannabinoid-based product being tested in a Phase 3 clinical trial (NCT03339622), currently recruiting, for its efficacy in relieving pain in people with advanced cancer.
The use of cannabinoids has grown exponentially for the treatment of a variety of health concerns. In my practice we have used full spectrum CBD products for several years with excellent results with fibromyalgia patients, cancer patients, or any chronic pain condition. CBD not only impacts the pain but positively affects mood, insomnia, and anxiety. CBD is well tolerated, and these products do not interfere with other medications. CBD can be vaporized, taken orally, applied topically or can be applied in combination.
Here is a link to the entire article.
For more information about #CBD, #ozone, #acupuncture, #nutrition and #integrative medicine please contact the acupuncture and integrative-medicine practice of Dr. Scott Denny with practice locations in Davie and Pompano Beach, Florida. Please also visit http://www.drscottdenny.com to complete your complimentary health analysis and receive a copy of Dr. Denny’s free eBook.